Second CAR T-Cell Therapy Approved for Myeloma

(MedPage Today) -- The FDA approved ciltacabtagene autoleucel (cilta-cel; Carvykti), the second chimeric antigen receptor (CAR) T-cell therapy for adults with relapsed or refractory multiple myeloma, Janssen Pharmaceuticals announced.
Ciltacabtagene...